- Sanofi (NASDAQ:SNY) announces that the Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
- The primary endpoint was complete remission from weeks 29 to 37 with minimal doses of corticosteroids (≤10/mg day). Complete remission was defined as the absence of new and established skin lesions.
- Results show the proportion of patients meeting the primary endpoint on rilzabrutinib was not significantly different from placebo.
- Rilzabrutinib’s safety profile remained consistent with previous results and no new safety signals were identified.